Department of Pathophysiology, School of Pharmacy, Showa University, Tokyo, Japan.
J Pharmacol Sci. 2009 Oct;111(2):221-5. doi: 10.1254/jphs.09205sc. Epub 2009 Sep 26.
We examined the effects of lomerizine on serotonin (5-hydroxytryptamine, 5-HT)-induced contraction of the basilar artery and compared them with those of nifedipine. Although both lomerizine and nifedipine completely blocked K(+)-induced vasoconstriction, 5-HT-induced vasoconstriction was more strongly inhibited by lomerizine than nifedipine. A 5-HT(2A) antagonist inhibited the 5-HT-induced vasoconstriction, but a 5-HT(1B) antagonist did not. Lomerizine, but not nifedipine, suppressed 5-HT-induced Ca(2+) release in 5-HT(2A)-expressing HEK293 cells. Moreover, neither antagonist affected ATP-induced Ca(2+) release. These results suggest that lomerizine may inhibit not only voltage-dependent Ca(2+) channels but also 5-HT(2A) receptors and so inhibit 5-HT-induced contraction in the basilar artery.
我们研究了洛美利嗪对基底动脉 5-羟色胺(5-HT)诱导收缩的影响,并将其与硝苯地平进行了比较。虽然洛美利嗪和硝苯地平均可完全阻断 K+诱导的血管收缩,但洛美利嗪对 5-HT 诱导的血管收缩的抑制作用强于硝苯地平。5-HT2A 拮抗剂抑制 5-HT 诱导的血管收缩,但 5-HT1B 拮抗剂没有。洛美利嗪而非硝苯地平抑制 5-HT2A 表达的 HEK293 细胞中 5-HT 诱导的 Ca2+释放。此外,两种拮抗剂均不影响 ATP 诱导的 Ca2+释放。这些结果表明,洛美利嗪不仅可能抑制电压依赖性钙通道,还可能抑制 5-HT2A 受体,从而抑制基底动脉中 5-HT 诱导的收缩。